267 related articles for article (PubMed ID: 21900105)
1. 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer.
Azzoli CG; Temin S; Aliff T; Baker S; Brahmer J; Johnson DH; Laskin JL; Masters G; Milton D; Nordquist L; Pao W; Pfister DG; Piantadosi S; Schiller JH; Smith R; Smith TJ; Strawn JR; Trent D; Giaccone G;
J Clin Oncol; 2011 Oct; 29(28):3825-31. PubMed ID: 21900105
[TBL] [Abstract][Full Text] [Related]
2. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
Masters GA; Temin S; Azzoli CG; Giaccone G; Baker S; Brahmer JR; Ellis PM; Gajra A; Rackear N; Schiller JH; Smith TJ; Strawn JR; Trent D; Johnson DH;
J Clin Oncol; 2015 Oct; 33(30):3488-515. PubMed ID: 26324367
[TBL] [Abstract][Full Text] [Related]
3. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
Hanna N; Johnson D; Temin S; Baker S; Brahmer J; Ellis PM; Giaccone G; Hesketh PJ; Jaiyesimi I; Leighl NB; Riely GJ; Schiller JH; Schneider BJ; Smith TJ; Tashbar J; Biermann WA; Masters G
J Clin Oncol; 2017 Oct; 35(30):3484-3515. PubMed ID: 28806116
[TBL] [Abstract][Full Text] [Related]
4. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
5. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.
Azzoli CG; Baker S; Temin S; Pao W; Aliff T; Brahmer J; Johnson DH; Laskin JL; Masters G; Milton D; Nordquist L; Pfister DG; Piantadosi S; Schiller JH; Smith R; Smith TJ; Strawn JR; Trent D; Giaccone G;
J Clin Oncol; 2009 Dec; 27(36):6251-66. PubMed ID: 19917871
[TBL] [Abstract][Full Text] [Related]
6. Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: results by performance status, EGFR mutation, histology and response to previous induction.
Tan PS; Lopes G; Acharyya S; Bilger M; Haaland B
Eur J Cancer; 2015 Nov; 51(16):2330-44. PubMed ID: 26364517
[TBL] [Abstract][Full Text] [Related]
7. Management of non-small cell lung in cancer patients with stable disease.
Grossi F
Drugs; 2012 Jun; 72 Suppl 1():20-7. PubMed ID: 22712794
[TBL] [Abstract][Full Text] [Related]
8. The PARAMOUNT trial: a phase III randomized study of maintenance pemetrexed versus placebo immediately following induction first-line treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer.
Gridelli C; Maione P; Rossi A
Rev Recent Clin Trials; 2013 Mar; 8(1):23-8. PubMed ID: 23259416
[TBL] [Abstract][Full Text] [Related]
9. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
10. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
11. Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Socinski MA; Evans T; Gettinger S; Hensing TA; VanDam Sequist L; Ireland B; Stinchcombe TE
Chest; 2013 May; 143(5 Suppl):e341S-e368S. PubMed ID: 23649446
[TBL] [Abstract][Full Text] [Related]
12. The Use of Systemic Treatment in the Maintenance of Patients with Non-Small Cell Lung Cancer: A Systematic Review.
Kulkarni S; Vella ET; Coakley N; Cheng S; Gregg R; Ung YC; Ellis PM
J Thorac Oncol; 2016 Jul; 11(7):989-1002. PubMed ID: 27013406
[TBL] [Abstract][Full Text] [Related]
13. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
14. Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer.
Paz-Ares LG; Altug S; Vaury AT; Jaime JC; Russo F; Visseren-Grul C
BMC Cancer; 2010 Mar; 10():85. PubMed ID: 20211022
[TBL] [Abstract][Full Text] [Related]
15. Advanced non-small cell lung cancer (NSCLC): maintenance therapy for all?
Hashemi-Sadraei N; Pennell NA
Curr Treat Options Oncol; 2012 Dec; 13(4):478-90. PubMed ID: 22972369
[TBL] [Abstract][Full Text] [Related]
16. Perspectives on salvage therapy for non-small-cell lung cancer.
Cappuzzo F; Finocchiaro G; Trisolini R; Toschi L; Bartolini S; Metro G; Crinò L
Oncology (Williston Park); 2005 Jul; 19(8):989-95; discussion 995-6, 999, 1003-4, passim. PubMed ID: 16131043
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
Bylicki O; Ferlay C; Chouaid C; Lavolé A; Barlési F; Dubos C; Westeel V; Créquit J; Corre R; Vergnenègre A; Monnet I; Le Caer H; Fournel P; Vaylet F; Falchero L; Poudenx M; Linard P; Pérol D; Zalcman G; Pérol M
J Thorac Oncol; 2013 Jul; 8(7):906-14. PubMed ID: 23591160
[TBL] [Abstract][Full Text] [Related]
18. Current and emerging therapies for patients with advanced non-small-cell lung cancer.
Sheth S
Am J Health Syst Pharm; 2010 Jan; 67(1 Suppl 1):S9-14. PubMed ID: 20044378
[TBL] [Abstract][Full Text] [Related]
19. Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline.
Noble J; Ellis PM; Mackay JA; Evans WK;
J Thorac Oncol; 2006 Nov; 1(9):1042-58. PubMed ID: 17409993
[TBL] [Abstract][Full Text] [Related]
20. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.
Pérol M; Chouaid C; Pérol D; Barlési F; Gervais R; Westeel V; Crequit J; Léna H; Vergnenègre A; Zalcman G; Monnet I; Le Caer H; Fournel P; Falchero L; Poudenx M; Vaylet F; Ségura-Ferlay C; Devouassoux-Shisheboran M; Taron M; Milleron B
J Clin Oncol; 2012 Oct; 30(28):3516-24. PubMed ID: 22949150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
